Solara Active Pharma Sciences Ltd
SOLARA Q3 FY25 earnings call: Order Book
Q3 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
No information is provided regarding the same in the latest conference call. No information is provided regarding the same in the latest conference call.
From Solara Active Pharma Sciences Ltd's Q3 FY25 earnings-call transcript · updated 15 Jul 2026.
Revenue & Sales Performance
Profitability & Margins
See what Solara Active Pharma Sciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Solara Active Pharma Sciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The transcript does not explicitly mention the current or expected order book or pending orders for Solara Active Pharma Sciences Limited.
- The company highlighted six key product approvals and 11 market extensions in Q3, focusing on portfolio maximization, new geographies, and new customers, which implies future order inflows.
- The CRAMS business order pipeline seems positive with plans to grow revenue to approximately Rs. 500 crores in 3-4 years.
- The Vizag CRAMS facility retrofit and investments suggest ongoing and future projects.
2 more points from Solara Active Pharma Sciences Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Solara Active Pharma Sciences Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹417 Cr, net profit ₹28 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Solara Active's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- SMS Pharma. (Q3 FY25)
Q3FY25 revenue from operations: ₹173.35 crore, up 7% YoY from ₹161.48 crore in Q3FY24 (Page 18, 5). Key concall takeaways from SMS Pharmaceuticals Ltd's Q3…
- Wockhardt (Q3 FY25)
725 crore, up 2% quarter-on-quarter and 2.2% year-on-year (Q3 FY24 revenue: Rs. Key concall takeaways from Wockhardt Ltd's Q3 FY25 earnings call — and how it…
- NGL Fine Chem (Q3 FY25)
Q3FY25 revenue from operations: ₹89.10 crores, a year-on-year (Y-o-Y) increase of 1.30% (Page 8). Key concall takeaways from NGL Fine Chem Ltd's Q3 FY25…
- Shree Ganesh Rem (Q3 FY25)
Q3FY25 Revenue from Operations:** ₹27.05 Cr . Key concall takeaways from Shree Ganesh Remedies Ltd's Q3 FY25 earnings call — and how it ranks against sector…
Arthneeti Pro · Annual
Solara Active Pharma Sciences Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Solara Active Pharma Sciences Ltd Q4 FY25 results?
No information is provided regarding the same in the latest conference call. No information is provided regarding the same in the latest conference call.
What is Solara Active Pharma Sciences Ltd share price analysis?
Solara Active Pharma Sciences Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹2,098. Investors should review the full earnings analysis for detailed insights.
Is Solara Active Pharma Sciences Ltd planning capital expenditure?
No information is provided regarding the same in the latest conference call.
Keep Solara Active Pharma Sciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.